Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Fiji Kava Limited ( (AU:CCO) ).
The U.S. Food and Drug Administration has confirmed that traditionally prepared kava beverages made solely from kava root and water are recognised as food under federal law, providing crucial regulatory clarity for The Calmer Co.’s kava powders in the United States while its tinctures, capsules and flavoured Taki Mai shots continue to be sold as dietary supplements. This dual positioning across both food and supplement categories strengthens the company’s competitive edge in what it calls the world’s largest kava market, reinforcing its fast-growing Amazon USA business where Fiji Kava’s instant kava remains the top branded product and Taki Mai has posted triple-digit gains in visibility and share of sales, underpinning an expanded push across retail, e-commerce and B2B channels.
The most recent analyst rating on (AU:CCO) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Fiji Kava Limited stock, see the AU:CCO Stock Forecast page.
More about Fiji Kava Limited
The Calmer Co. International Limited, listed on the ASX as CCO, is a consumer packaged goods company specialising in kava-based beverages, natural relaxation products and healthier alternatives to alcohol. Through its Fiji Kava and Taki Mai brands, the company targets the U.S. and global markets with instant kava powders, shots, tinctures and capsules, supported by an FDA-registered, cGMP-compliant manufacturing facility in Fiji and a growing presence on Amazon USA.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.18M
For a thorough assessment of CCO stock, go to TipRanks’ Stock Analysis page.